J&J Faces Further Criticism Over Bedaquiline Despite Licensing Deal
Agreement With Stop TB Partnership Allows For Generic Versions Of Sirturo In LMICs
Johnson & Johnson has reached an agreement with the Stop TB Partnership that will allow generic bedaquiline versions of the firm’s Sirturo brand to be supplied in LMICs where patents remain in effect – but critics say the deal does not go far enough.
